Research programme: therapeutic proteins - Multicell Technologies

Drug Profile

Research programme: therapeutic proteins - Multicell Technologies

Alternative Names: Recombinant I(alpha)Ip - Multicell Technologies; Therapeutic protein for sepsis - Multicell Technologies

Latest Information Update: 08 Jun 2010

Price : $50

At a glance

  • Originator MultiCell Technologies Inc
  • Class Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Sepsis

Most Recent Events

  • 19 Oct 2005 Preclinical trials in Sepsis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top